Condensing peptide-DNA complexes have great potential as nonviral agents for gene delivery. To date, however, such complexes have given transfection activities greatly inferior to adenovirus and somewhat inferior to cationic lipid-DNA complexes, even for cell lines and primary cells in vitro. We report here the identification of a novel condensing peptide, CL22, which forms DNA complexes that efficiently transfect many cell lines, as well as primary dendritic and endothelial cells. We report studies with sequence and structure vari-
Introduction
Vectors giving efficient delivery of DNA from an extracellular location to the nucleus of target cells are required for gene therapy, for other modern approaches to drug discovery (such as functional genomics) and for fundamental research into the function and control of mammalian genes. Although several viral vectors can give efficient gene delivery, their use for research applications is usually slow and labour-intensive, and their utility for gene therapy limited by DNA carrying capacity, difficulties in reliable and cost-effective manufacture, and by immunogenicity and other safety concerns. [1] [2] [3] At the present time nonviral vectors typically give lower transfection efficiencies than adenovirus (the most efficient viral vector), and also give large variability in transfection efficiencies between cell types. They have the advantages, however, of increased DNA carrying capacity, lower immunogenicity, greater flexibility and greater simplicity of preparation, purification and storage.
Most nonviral gene delivery strategies use synthetic molecules to condense DNA to reduce its size and alter its charge, thus facilitating nuclear access across cell membrane barriers. Nonviral transfection agents reported in the literature include polydisperse cationic polymers such as polylysine, 4 ,5 defined length oligolysines, 6, 7 polyarginine, 8 polyethyleneimine, [9] [10] [11] [12] Starburst dendrimers 13, 14 or cationic lipids. [15] [16] [17] Although many of ants that define some properties of the peptide that contribute to efficient transfection. We demonstrate that the superior transfection activity of CL22 compared with other DNA condensing peptides is conferred at a step after uptake of the complexes into cells. We show that CL22-DNA complexes have transfection activity that is at least equivalent to the best available nonviral agents. Gene Therapy (2001) 8, 99-110.
these are reported to transfect various cell lines in vitro with useful efficiency, few give reproducible transfection of primary cells ex vivo. Only a few cationic lipids, polyethyleneimine and combinations of cationic polymer and lipid give significant transfection in vivo, and even for these agents transfection in vivo is substantially poorer than in vitro. Although used less commonly, cationic peptides of defined length have much potential as transfection agents. They offer greater reproducibility of synthesis, lower heterogeneity and hence greater reliability of transfection than most nonviral alternatives, as well as biodegradability and low toxicity. A large number of commercially available natural and non-natural amino acid building blocks enable the preparation and testing of peptide-DNA complexes differing substantially in physicochemical or biological character. Modern peptide synthesis and bioconjugation strategies, which can utilise the different reactive groups available on peptides, allow for facile, site-specific attachment of additional peptidic or nonpeptidic entities to the cationic condensing peptide. 18 Such entities may be attached to reduce unwanted, nonspecific interactions between the complex and plasma components or extracellular matrix in vivo, and confer specific uptake into target cells or improved intracellular trafficking.
In this paper, we describe a 35 amino acid cationic peptide, CL22, which forms complexes with DNA that give efficient transfection of mammalian cells in vitro and ex vivo. The sequence of CL22, NH 2 -KKKKKK GGFLGFWRGENGRKTRSAYERMCNILKGKCOOH, was designed to incorporate three domains. It has a lysinerich N-terminus to facilitate DNA condensation and a Cterminal sequence derived largely from influenza nucleoprotein, joined by a sequence GGFLGF designed for cleavage by the abundant endosomal endoprotease cathepsin D. 19, 20 The C-terminal domain corresponds to residues 206-225 of influenza nucleoprotein, a sequence believed to comprise an epitope presented on class II molecules of the human leukocyte antigen (HLA) complex. 21 CL22 was originally designed to explore the concept of using peptide-DNA complexes to deliver both peptide epitopes and plasmid encoding intact nucleoprotein to professional antigen presenting cells in order to achieve presentation of epitopes on HLA class I and II molecules for vaccine purposes. CL22 complexes give maximal transfection when the peptide is in the dimeric form, [CL22] 2 . Spontaneous dimerisation occurs through formation of a disulphide bond between cysteine residues close to the C-terminus. We report here that [CL22] 2 -DNA complexes unexpectedly give transfection efficiencies for immortalised cell lines in vitro and primary human cells ex vivo that are greatly superior to those of defined polylysine complexes. We present data relating transfection efficiency to biophysical properties of the [CL22] 2 -DNA complexes, and which show that these complexes compare favourably for transfection efficiency with the best commercially available nonpeptide transfection agents.
Results
Characterisation of [CL22] 2 :DNA interaction and complexes Gel shift analysis of [CL22] 2 -DNA complexes confirmed that [CL22] 2 bound to DNA and indicated that condensation into complexes occurred at charge ratios between 1 and 2 (data not shown). Photocorrelation spectroscopy (PCS) and potential measurements were used to assess the size (Z Av) and potential (which relates to surface charge) of complexes formed between plasmid DNA and [CL22] 2 in HEPES (10 mm HEPES buffer pH 7.4) (Figure 1a ). Increasing the charge ratio at which the complexes were prepared resulted in a shift in their potential from anionic to cationic. At the point of zero potential (between charge ratio 1.1 and 1.2), aggregation of the particles occurred, as indicated by the Z Av increasing to exceed 1500 nm. Above and below the point of zero potential, complexes had a Z Av of approximately 100 nm. The typical polydispersity of such samples was 0.2, suggesting that the results of particle sizing could be interpreted with some confidence. Complexes prepared in HEPES were stable with respect to particle size on storage up to at least 3 days (data not shown).
To confirm size and homogeneity, and to analyse shape, complexes were imaged by cryo-electron microscopy (cryo-EM).
[CL22] 2 -DNA complexes formed in HEPES comprised boulder-like particles with an average diameter of 40-80 nm (Figure 2 ), in agreement with PCS analysis. PCS analysis of complexes prepared in HBS (10 mm HEPES buffer pH 7.4 containing 150 mm NaCl) were much larger than those prepared in the absence of NaCl, and continued to aggregate over a period of 1-2 h, after which time the preparations showed a Z Av exceeding 1500 nm ( Figure 1b) and a high polydispersity. DNA complexes for all cell types tested. The magnitude of the enhancement varied between cell types, and the effect was dependent on chloroquine concentration. The optimal chloroquine concentrations were 120 m for most cell types tested, except for HepG2 and Hepa1-6 which were 90 m, and human dendritic cells (DC) which were 40 m (data not shown). Higher concentrations led to toxicity.
The effects on transfection activity of [CL22] 2 peptide:DNA ratio, exposure time of the cells to complexes, and presence or absence of NaCl during complex formation were examined for HepG2 and KLN 205 cells, using the ␤-gal expression plasmid pCMV␤ and optimal chloroquine concentrations. Increasing the incubation time of cells with complexes gave improved transfection up to 4-5 h (data not shown). Condensation in the presence of HBS rather than HEPES enhanced transfection of KLN 205 cells at charge ratios greater than 1.1 ( Figure 3 ) and this was also observed with HepG2 cells and Cos 7 cells (data not shown). Optimal transfection for complexes prepared in HEPES was observed at a charge ratio of 1.1, at which PCS analysis demonstrated that the particles were aggregated (Figure 1b) . Optimal transfection for complexes prepared in HBS was at charge ratio 1.6-2 for nearly all cell types tested. These data suggest aggregation enhances transfection in vitro. Mild centrifugation (5 min at 200 g) of the cell culture plates after addition of the complexes also enhanced transfection approximately three-fold (data not shown), presumably by improving contact of complexes with the cell surface.
Effects of peptide sequence and structure on transfection In the experiments described above CL22 was in the form of a dimer, [CL22] 2 , resulting from spontaneous disul- We observed that for several cell lines the transfection activity of [CL22] 2 was reduced by more than 100-fold if the peptide was incubated in 5 mm DTT before complex formation. Control experiments demonstrated that DTT at the concentration used had no effect on nonreducible transfection agents. To confirm that the effect of DTT was due to the poor transfection ability of CL22 in monomeric form, the single cysteine thiol of CL22 was reacted with N-ethylmaleimide (NEM) to prevent any possibility of dimer formation during transfection. Figure 4a (Figure 4a ), suggesting that rapid intracellular reduction of the dimer of CL22 is not important in transfection.
In dimeric form CL22 has a net charge of +22. To determine whether the high transfection activity of [CL22] 2 was due simply to an optimal net charge, a series of defined oligolysine peptides containing 12 (NBC37), 18 (NBC28), 24 ([NBC37] 2 ) or 72 ([NBC32] 2 ) lysines with net charges of +12, +18, +24 or +72, respectively, was prepared and assayed. In addition we assayed a polydisperse polylysine containing an average number of 250 lysines per polylysine chain (pLL). Figure 4a shows that complexes made with both defined and polydisperse polylysines transfected KLN 205 cells poorly compared with [CL22] 2 , irrespective of net charge, with activity on average 10-fold lower. Among the polylysines there appeared to be a relationship between net charge and transfection activity, with activity decreasing with increasing net charge. Unlike CL22, dimerisation of the oligolysine peptide NBC37 led to a decrease in transfection activity.
Since these data showed the high transfection activity of [CL22] 2 cannot simply be attributed to its net charge, we investigated the importance of charge density. The nucleoprotein epitope of CL22 has seven positively charged residues with a dispersed distribution. A series of peptides (NBC38, NBC40 and NBC39) with differing charge densities was prepared using lysine to convey cationic charge and serine as a neutral hydrophilic 'spacer' residue to decrease charge density. Each peptide was tested as a monomer, with a net charge of +12, or as a dimer with a net charge +24. The peptides with dispersed charge showed improved transfection of KLN 205 cells over corresponding high charge density oligolysine peptides with the same net charge (Figure 4a ). Dimerisation of NBC38 and NBC40, which effects an increase in net charge of each peptide, again resulted in a decrease in transfection activity. Dimerisation of NBC39, however, was not detrimental to transfection activity. These data suggest the dispersed charge distribution in the nucleoprotein epitope of CL22 may contribute to its high transfection activity. The possibility that the exact amino acid sequence of the nucleoprotein epitope is important was examined using a peptide, CL28, in which the order was randomised. Figure 4b shows that a minimum N-terminal stretch of four or five lysines is required for optimal transfection activity. Even though the net charge of [CL36] 2 is +14, transfection activity was negligible compared with that of [CL22] 2 . Increasing the number of N-terminal lysines to 12, in the peptide CL26, did not significantly improve transfection activity.
In order to investigate the possible contribution of the protease cleavage sequence 'GGFLGF' to transfection activity, we made and tested a variant (CL25) in which this motif was replaced by FGLGGF. The transfection activity of [CL25] 2 was 40% of that displayed by [CL22] 2 and substantially greater than the oligolysines (Figure 4b ), suggesting that efficient release of the nucleoprotein epitope by protease cleavage in the endosome is not an absolute requirement for transfection activity. We observed that a variant [CL41] 2 in which the entire CL22 sequence was reversed, gave transfection activity very similar to that of [CL22] 2 . The result with this peptide suggested first that the precise order of residues in the nucleoprotein epitope is not crucial, and second that high transfection activity does not require the dense cationic charge to be N-terminal; a C-terminal location is also compatible with good transfection.
Finally, we observed that the variant CL33, in which the charged residues of the nucleoprotein epitope were replaced with neutral serine residues, gave very low transfection activity (Figure 4b ). These results raised the possibility that the overall DNA condensing power of CL22 is the key factor conferring its high transfection activity. To investigate this possibility ethidium bromide (EtBr) exclusion assays were conducted to investigate whether transfection activity of peptide-DNA complexes correlates with maximal extent of DNA condensation. The results of these assays for CL22 monomer and dimer and a series of other relevant peptides are given in Figure 5 . CL22 and NBC37 monomers were prepared by pre-treatment with 5 mm DTT. DTT was confirmed to have no effect on EtBr exclusion by carrying out exclusion assays on DTT-treated and -untreated peptides lacking a cysteine residue (data not shown). Peptides with much greater DNA condensing power than (Figure 4a ). These data demonstrate very clearly that the higher transfection activity of [CL22] 2 compared with other peptides cannot be attributed to superior uptake of the complexes, and therefore must result from more favourable intracellular trafficking, DNA uncoating or expression. Figure 8 . Transfection efficiencies exceeding 10% were observed for all the immortalised cells, and exceeding 15% for both primary cell types. For five of the seven cell lines tested efficiencies exceeded 30%, and for HeLa and COS-7 cells they exceeded 70%.
Comparison of [CL22] 2 with commercially available transfection agents
The transfection activity of [CL22] 2 complexes was compared with that of 11 commercially available nonviral transfection agents, including cationic lipid and nonpeptide polymers, using the tumour cell line HepG2 and primary HUVEC. The results are given in Figure 9. [CL22] 2 -DNA complexes gave significantly higher HepG2 transfection than all the other formulations except Effectene, which gave equivalent activity. On HUVEC, [CL22] 2 -DNA complexes gave transfection activity similar to Fugene 6 and ExGen500, and much higher than the other formulations.
Discussion
Transfection of mammalian cells with DNA complexes was first reported over a decade ago 22 using heterogeneous polylysine as the condensing agent. Such polylysine-DNA complexes give transfection activity that is too low to be of general use as a transfection agent, especially for primary cells. Defined length oligolysines have advantages over heterogeneous polylysine in purification and homogeneity, but generally give equally inefficient transfection. 7 A small number of alternative condensing peptides have been reported to give more efficient transfection of one or two immortalised cell lines. These include an 18mer oligolysine with a single tryptophan residue, 6 a 19mer oligolysine with a 30 amino acid C-terminal extension derived from the DNA binding region 
Figure 7 Effects of serum on transfection and uptake with [CL22] 2 -DNA complexes. Transfection of KLN 205 cells (a) and HepG2 cells (b) in six-well plates in the presence of the indicated amounts of FCS. [CL22] 2 -pCMV␤ complexes were prepared in HEPES at charge ratio of 1.6. (c) Transfection of KLN 205 cells in six-well plates in the presence of 10% FCS. [CL22] 2 -pCMV␤ complexes were prepared in HEPES at the indicated charge ratios. (d) Uptake of [CL22] 2 -YOYO-1 labelled DNA complexes into KLN 205 cells in presence (red) and absence (black) of 10% FCS. Complexes were prepared in HEPES at a charge ratio of 1.6. Cellular autofluorescence control from untreated cells (dotted lines); binding from 4°C control (thin lines); binding and uptake at 37°C (thick lines).
of an anti-DNA antibody, 23 a 19mer oligolysine with a 20 amino acid extension derived from adenovirus fibre protein, 24 and a peptide designed from the natural DNA binding protein, human histone H1. 25 The basis of the improved transfection activity for these peptides has not been elucidated, but in the cases of the extended oligolysines it was speculated to involve enhanced intracellular trafficking.
The condensing peptide [CL22] 2 unexpectedly gives efficient transfection of all immortalised cell lines and both primary human cell types we have tested. Our efforts to define precisely the physical properties of [CL22] 2 which endow it with good transfection activity are still ongoing, but the studies reported in this paper provide some insight. It is striking that dimerisation is required for high transfection activity. Since our studies show there is no simple relationship between DNA condensing activity and transfection activity of condensing peptides, the results imply that a certain minimum threshold of condensing power is required for efficient transfection. CL22 monomer is below the threshold and CL22 dimer above it. The possibility that intracellular reduction of the disulphide linking the two monomers of [CL22] 2 plays a part in releasing DNA within the cell is unlikely, because the thioether-linked dimer, BMH-[CL22] 2 , which should be much more resistant to intracellular reduction, gave transfection activity equivalent to [CL22] 2 . In addition, disulphide dimerisation did not improve transfection activity of the oligolysine complexes.
Our data suggest that high transfection activity requires more than three consecutive lysine residues at one terminus of the condensing peptide, which is also consistent with the idea that a minimum threshold of DNA condensing power is required. The cathepsin cleavage sequence, GFLGF, is not absolutely required for the high transfection activity of CL22, since altering the sequence to GLGGF (CL25) gave only slightly reduced transfection. Furthermore it is possible that chloroquine may inhibit the activity of lysosomal enzymes anyway, by buffering the lysosome, which would further support the observation that cleavage of the peptide at this Gene Therapy sequence is not required for optimal activity. It is the 24-residue sequence derived from influenza nucleoprotein that confers high transfection activity upon the terminal oligolysine, although the precise order of residues in the nucleoprotein-derived sequence is unimportant. Whatever the key physical properties for transfection are, they do not appear to exert their effect by improving uptake into cells, since [CL22] 2 -DNA complexes are taken up with an efficiency similar to that of oligolysine-DNA complexes yet give much higher transfection activity. This suggests that the enhancement of transfection by CL22 is mediated within the cell. The more obvious possibilities are that CL22 confers more favourable resistance to endonucleases, transport to the nucleus, DNA uncoating or endosome escape. Improved endonuclease resistance appears unlikely, because oligolysine-condensed DNA has been shown to be resistant to these enzymes. 26, 27 The nucleprotein-derived sequence of CL22 does not contain known primary sequence motifs likely to aid nuclear localisation. CD measurements of [CL22] 2 indicated that the peptide contains approximately 8% ␣ helical content in aqueous buffer at pH 7, increasing to 35% in the presence of the secondary structure promoting solvent trifluoroethanol (data not shown). This amphipathic helicity might contribute to favourable intracellular trafficking through improved membrane interaction, although assays involving external lysis of erythrocytes or other cells indicate [CL22] 2 does not disrupt membranes (data not shown). In addition, [CL22] 2 requires chloroquine for efficient transfection.
Our PCS and cryo-EM measurements suggest [CL22] 2 condenses DNA to give particles of regular shape, low polydispersity (0.15) and 40-100 nm in diameter at low DNA concentration (20 g/ml), in the absence of salt and at charge ratios exceeding 1.1. We used cryo-EM because, unlike the more commonly used transmission EM, this technique images particles in their hydrated state in solution, is not dependent on adherence of particles to a surface and does not require heavy metal staining. CryoEM therefore gives meaningful measurements of particle size.
Our data suggest particle size is an important parameter for transfection of cells in vitro. Preparation of [CL22] 2 -DNA complexes at a charge ratio of 1.1 in saltfree conditions, or in the presence of 150 mm NaCl, led to aggregation, with formation of polydisperse particles for which PCS analysis indicated a Z Av exceeding 1 m. Light microscopy of biotinylated [CL22] 2 -DNA complexes incubated with a Texas red-streptavidin conjugate and mixed with fluorescent beads of various sizes confirmed the size of these large complexes (data not shown). Conditions giving these partially aggregated preparations gave the highest transfection activity. Incubation in serum has been reported to reduce aggregation with PEI-DNA particles. 28 Transfection in the presence of serum resulted in decreased expression with KLN 205 cells, but not with HepG2 cells. We showed that serum also reduced the uptake of [CL22] 2 -DNA complexes by KLN 205 cells. Using light microscopy of biotinylated [CL22] 2 -DNA complexes incubated with Texas red-streptavidin and mixed with fluorescent beads of various sizes, we have observed that serum reduces the saltinduced aggregation of the complexes (data not shown), as has also been observed for PEI-DNA complexes. 28 These observations indicate that transfection conditions affect various cell lines differently. It may be that the opti-
Figure 9 Comparison of transfection activity of [CL22] 2 -DNA complexes with complexes prepared using commercially available transfection agents. (a) Transfection of HepG2 cells, (b) transfection of HUVEC. Complexes were prepared as detailed in Material and methods. Transfections were carried out in the presence of 10% serum. Cells were transfected with pCMVLuc complexes (0.5 g per well DNA) in triplicate in 96-well plates for 4 h (HepG2) and 1 h (HUVEC) as detailed in Materials and methods. Transfection with [CL22] 2 -pCVMLuc complexes was carried out in the presence of 90 m chloroquine. Each point was carried out in triplicate. The results show the means derived from at least two such experiments for each transfection agent.
mal particle size for transfection varies between different kinds of cells, being larger for KLN 205 than for HepG2. However, it is also possible that serum influences transfection activity through effects on the potential rather than the size of complexes, or through effects on intracellular trafficking or cellular metabolism. Other work 29 has shown that albumin changes the potential for polylysine-DNA complexes from cationic to anionic, which would affect cell surface binding through electrostatic interactions.
Our observations that [CL22] 2 -DNA complexes give efficient (Ͼ10%) transfection of all cell types tested suggest it has general utility as an in vitro or ex vivo transfection agent. Although adenovirus gives very efficient transfection of many cell types in vitro (at least when very high multiplicities of infection are employed), construction and propagation of each recombinant virus takes several weeks. In contrast, CL22-mediated transfection can be accomplished very rapidly.
[CL22] 2 -DNA complexes transfect the cell line HepG2 and primary HUVEC as efficiently as the best commercially available nonpeptide agents, including cationic lipids and PEI ExGen 500. Our recent work shows that the average transfection efficiency of human DC with [CL22] 2 -DNA complexes (17%) is greatly superior to alternative nonviral transfection agents. 30 Such primary DC are generally refractory to transfection. 31, 32 Our results with [CL22] 2 -DNA complexes are inconsistent with this hypothesis. Efficient DC transfection by [CL22] 2 -DNA complexes is an important observation, because immunisation with DC transfected ex vivo with genes expressing disease-associated antigens is one of the most promising approaches to immunotherapy of cancer and severe infectious diseases. We are presently developing protocols for evaluating DC transfected with genes for tumour-associated antigens as therapeutic vaccines in cancer patients. We are also presently evaluating whether the nucleoprotein epitope of CL22 is presented on HLA class II molecules.
In summary, CL22 is a novel peptide which gives in vitro transfection efficiencies for immortalised and tumour cell lines that compare favourably with the best nonpeptide polymer and cationic lipid formulations, and gives unexpectedly efficient transfection of primary human dendritic and endothelial cells.
Materials and methods

Chemicals and reagents
Galacto-light and Luc-screen kits were obtained from Tropix/PerkinElmer, Bedford, MA, USA. X-gal was obtained from Life Technologies, Paisley, UK. Protein estimations were made using a DC protein assay kit (BioRad Laboratories, Hemel Hemstead, UK). Transfection reagents were obtained from the following suppliers: Effectene and Superfect from Qiagen (Crawley, UK); Tfx-10, Tfx-20 and Tfx-50 from Promega (Southampton, UK); Clonfectin from Clontech Laboratories (Basingstoke, UK); ExGen500 from Euromedex (Souffelweyersheim, France); Lipofectin and LipofectAMINE from Life Technologies (Paisley, UK); DOTAP (Dioleoly,1,2 diacyl-3-trimethyl ammonium propane); FuGENE 6 from Boehringer, Mannheim, Germany and poly-l-lysine (pLL) 250mer HCl from Sigma. Peptide synthesis reagents were from PE Biosystems (Warrington, UK), and all other chemicals were from Aldrich (Poole, UK) unless otherwise stated.
Peptide synthesis, purification and analysis Peptides were prepared by solid phase peptide synthesis using standard Fmoc chemistry. HPLC analysis indicated all were at least 90% pure. The synthesis was accomplished using a Biosearch 9050 plus Pepsynthesizer in extended synthesis cycle mode. Lysine and tryptophan side chains were Boc protected; arginine side chains were Pbf protected; serine, threonine and tyrosine side chains were tBu protected; asparagine and cysteine side chains were Trt protected and glutamate side chains were tBu protected. The amino acid derivatives were coupled in a four-fold molar excess using 0.6 m O-(1H-benzotriazo-1-yl)tetramethyluronium tetrafluoroborate (TBTU)/0.9 m N-ethyldiisopropylamine in dimethylformamide as activating agents. TBTU was obtained from Alexis Biochemicals (Nottingham, UK). Deprotection of the N-terminal Fmoc group before each coupling was achieved using a solution of 20% piperidine in dimethylformamide (1 min at high flow rate followed by 10 min at 3 ml/min). The coupling time for each residue was 1.5 h. On completion, the resin-conjugated peptide was washed with dichloromethane and dried. The peptides were cleaved from the resin using trifluoroacetic acid/triisopropylsilane/ thioanisole/1,2-ethanedithiol (92.5: 2.5: 2.5: 2.5) for 1.5 h at room temperature, which simultaneously deprotected the amino acid side chains. The resin was then removed by filtration and washed with trifluoroacetic acid. The combined filtrate and washings were concentrated by evaporation then precipitated using diethyl ether followed by centrifugation to give the crude peptides. These were dissolved in a minimum volume of 20 mm ammonium acetate; pH 4.6 and purified using a Sephadex G25 (Superfine, Amersham Pharmacia Biotech, Little Chalfont, UK) gel filtration column (100 × 2.6 cm) run in the same buffer. The fractions containing peptide, as determined by analytical RP-HPLC, were pooled and lyophilised. Further purification was achieved by preparative HPLC using a C18 RP-HPLC column (Dynamax 83-221-C) (Rainin Instruments, Woburn, MA, USA) and a gradient of 20-50% acetonitrile (0.1% trifluoroacetic acid) in water (0.1% trifluoroacetic acid) over 30 min. The fractions corresponding to the major peak on the chromatograph were pooled and lyophilised. Finally, the peptides were desalted using a Sephadex G15 (medium) gel filtration column (70 × 2.6 cm) run in 20 mm ammonium acetate, pH 4.6. The peptide fractions, which were detected by analysis at 226 nm, were pooled and lyophilised. The pure peptides were stored at −20°C. The peptides were characterised using MALDI-TOF (matrix assisted laser desorption/ionisation time of flight) mass spectrometry. 0.1-0.5 mg of peptides was dissolved in 1 ml of 0.1% trifluoroacetic acid, and 0.5 l applied to the target and analysed using a Kratos Kompact MALDI IItDE spectrometer (Kratos Analytical, Manchester, UK). In each case the observed mass was within one mass unit of that expected.
Preparation of NEM-CL22
Six mg (1.5 mol) CL22 was dissolved in 0.9 ml PBS and the cysteine reduced by adding 3 mg (20 mol) DTT in Gene Therapy 0.1 ml water. After 2 h at 22°C the DTT was removed by gel filtration using a 1.6 × 30 cm column packed with Sephadex G25 Fine, equilibrated in 20 mm ammonium acetate, pH 5.0. Fractions containing peptide were collected, pooled and lyophilised. The molar ratio of free thiol to peptide, as determined by an Ellman's assay, was 0.88. To 0.9 ml of freshly reduced CL22 resuspended to 4 mg/ml in PBS, 100 l water containing 0.8 mg (6.4 mol) N-ethylmaleimide (NEM) was added. After 3 h incubation at 22°C an Ellman's assay failed to detect the presence of free thiols. The excess NEM was removed by gel filtration, as described above, before lyophilisation to give 2.1 mg thiol-blocked CL22. Analysis by MALDI-TOF mass spectrometry gave an observed molecular weight of 4227.8 (expected molecular weight 4227.0).
Preparation of peptide dimers
To form disulphide linked peptide dimers, typically 0.5-1.0 ml of 5 mg/ml of the peptide in water was added to 1.0 ml 0.1 m sodium borate pH 8.0. The cysteine thiols were left to oxidise in air at 22°C. The progress of dimerisation was followed by observing the change in retention time by capillary electrophoresis. After 16 h the peptide was judged to have dimerised completely. Addition of 10 mm DTT to a peptide sub-sample reversed the observed shift in retention time. Dimer formation was also confirmed by gel filtration analysis using a Superdex (HR10/30) column (Amersham-Pharmacia). Finally, the sodium borate salt was removed by gel filtration in ammonium acetate followed by lyophilisation. The final dimer products were confirmed by gel filtration on a Superdex HR10/30 column to be Ͼ90% in dimeric form, and by MALDI-TOF mass spectroscopy to have molecular weights within one mass unit of that predicted.
Preparation of BMH-[CL22] 2
To prepare cross-linked [CL22] 2 , 20 mg (4.9 mol) of CL22 was made up to 1.0 ml with 25 mm HEPES, pH 7.2. The homobifunctional cross-linker, 1,6 bis-(maleimido) hexane (0.7 mg; 2.5 mol, from Molecular Biosciences, Colorado, USA), was added as a solid to the stirred peptide solution, and left for 1 h at 22°C. The reaction mixture was purified by gel filtration on Sephadex G-25 to remove any unreacted linker. No further purification was necessary. The peptide was characterised using capillary electrophoresis, HPLC and MALDI-TOF mass spectrometry. Mass spectrometry gave an observed molecular weight of 8480.4 (expected molecular weight = 8480.0). Capillary electrophoresis analysis was used to confirm that the BMH-[CL22] 2 was free from monomeric and disulphide-linked peptide.
DNA pCMV␤ and pEGFP-N1 plasmids were obtained from Cambridge Biosciences, UK. pCMVluc was obtained by ligating the luciferase gene from pGL3 (Promega) into pCMV. 33 Plasmids were grown in DH5␣ cells in 5 litre fermentations in T broth (Gibco) containing ampicillin at 100 g/ml and were purified using Ultrapure 100 kit and column (Qiagen).
Ethidium bromide exclusion assays pCMV␤ DNA at 14 g/ml in 10 mm HEPES was labelled with ethidium bromide (EtBr) by mixing with an equal volume of 4 m EtBr in 10 mm HEPES pH 7.4. EtBr-lab-elled DNA was then condensed by adding an equal volume of condensing agent, (typically 1 ml + 1 ml), to give the desired charge ratio. Fluorescence was read 30 min after addition on a Jenway 6200 fluorimeter (Jenway, Dunmow, UK), ex = 492 nm, em = 520 nm, using narrow band pass filters, and then re-checked 1 h later. In no cases did the fluorescence change significantly from the initial reading. Monomer peptides were prepared by preincubation overnight with 5 mm DTT before condensation. DTT did not affect ethidium bromide exclusion of non-dimerized peptides. The fluorimeter was calibrated to 1 unit with 1 m ethidium bromide, and to 1000 units with 3.5 g/ml DNA and 1 m EtBr.
Cryo-electron microscopy Plasmid DNA was condensed as described for transfection assays. A drop (approximately 4 l) of sample was loaded on to both sides of either bare or holey carboncoated copper 400-mesh grids. The drop was briefly blotted and grids immediately plunged into freezing ethane cooled by liquid nitrogen. Sample grids were stored in liquid nitrogen and analysed on a Philips CM10 electron microscope (FEI Company, Eindhoven, The Netherlands) under low-dose mode.
Photocorrelation spectroscopy and potential measurements All buffers, DNA and peptides were filtered through 0.22 m filters (Millipore) before DNA condensation. The concentrations of DNA and peptide stocks were rechecked after filtering, by measuring absorbance at 260 nm and 280 nm, respectively. Plasmid DNA was condensed as described for transfection assays. For PCS, 200 l of sample was analysed in a small volume cuvette in an Autosizer 4700 (Malvern Instrument) at 25°C, at an angle of 90°, and 100 m aperture. For potential measurements, 3 ml of sample was analysed using a Zeta Sizer 3000 (Malvern Instruments) at 25°C. A minimum of three measurements consisting of 10 sub-runs each was taken for both PCS and analysis.
Cells and cell culture
The cell lines HeLa (human cervical adenocarcinoma), HepG2 (human hepatoma), KLN 205 (mouse lung squamous carcinoma), COS-7 (monkey kidney), 293 (human kidney), and Hepa1-6 (mouse hepatoma) were obtained from the American Type Culture Collection. HNX-14C (human oral cavity squamous carcinoma) was a gift from the Cancer Research Unit, University of Newcastle upon Tyne, UK. Human umbilical vein endothelial cells (HUVEC) were purchased from Promocell, Heidelburg, Germany. Human DC were prepared according to the procedure of Romani et al. 34 HepG2, COS-7 and Hepa1-6 were grown in DMEM (Sigma) supplemented with 10% fetal calf serum (FCS). HeLa, KLN 205 and 293 cells were grown in EMEM (Sigma) supplemented with 1% non-essential amino acids (NEAA) (Sigma) and 10% FCS. HNX-14C were grown in RPMI-1640 (Sigma) supplemented with 10% FCS. HUVEC were grown in endothelial growth medium (Promocell), and all flasks or wells used for HUVEC culture were precoated with 0.1% porcine gelatin. Human DC were grown in RMPI-1640 supplemented with 50 m ␤-mercaptoethanol, 1% NEAA (Sigma), 800 U/ml GM-CSF (LeucoMax) (Sandoz/Schering-Plough, Horsham, UK) and 500 U/ml IL-4 (PeproTech, London, UK).
Preparation of DNA complexes for transfection
Charge ratios were calculated as previously described. 35 The average molecular weight of a DNA base was taken as 330, the mass of CL22 was taken as 4101.9 with a net charge of +11.
Peptide-DNA complexes: Peptides were diluted to an appropriate concentration for final charge ratio in either HEPES (10 mm HEPES buffer pH 7.4) or in some cases HBS (10 mm HEPES buffer, 150 mm NaCl pH 7.4). This was rapidly mixed with an equal volume of plasmid DNA at 40 g/ml in the same buffer and incubated for 1 h at room temperature before transfection. To prepare complexes with monomers, peptides at 200 g/ml were treated overnight with 5 mm DTT.
Polylysine-DNA complexes: These were prepared in an identical manner as for peptide-DNA complexes.
Clonfectin: Two hundred g Clonfectin was resuspended in 180 l 10 mm HEPES-NaCl (Clontech), pre-warmed to 45-55°C. pCMVLuc, at 6.65 g/ml in HEPES-buffered RPMI-1640 in polystyrene tubes was mixed with an equal volume of Clonfectin solution diluted appropriately in HEPES-buffered RPMI (Clonfectin added to medium) to give ratios of 0.5:1, 1:1, 2:1, and 3:1 (g Clonfectin:g DNA). Complexes were incubated for 10-30 min before addition to cells. Cells were transfected in the absence of antibiotics.
DOTAP: Forty g/ml pCMVLuc was mixed with an equal volume of DOTAP diluted appropriately in HEPES-buffered RPMI-1640 (DOTAP added to buffer) to give ratios of 5:1, 10:1, 15:1, 20:1 (g DOTAP:g DNA).
Complexes were incubated for 15 min at room temperature before addition to cells.
Effectene: pCMVLuc at 0.32 mg/ml in HEPES was diluted with EC buffer (Qiagen) to 7.2 g/ml and treated with 8 l enhancer (Qiagen) per g DNA to a final concentration of 6.7 g/ml and incubated for 2-5 min. 320 l Effectene, appropriately diluted in EC buffer, was added to 480 l pCMVLuc/enhancer to give ratios of 5:1, 10:1, 25:1 and 50:1 (g Effectene: g DNA) and a final DNA concentration of 4 g/ml. This was incubated for 5-10 min at room temperature before addition to cells.
ExGen 500: pCMVLuc at 40 g/ml in 150 mm NaCl was mixed with an equal volume of ExGen 500 diluted in 150 mm NaCl to appropriate concentrations to give ratios of 3:1, 9:1, 12:1 and 15:1 (N:P). Complexes were incubated for 10 min at room temperature before addition to cells.
FuGENE 6: FuGENE 6 was diluted appropriately in HEPES-buffered RPMI-1640, with care taken to ensure that it did not come into contact with plastic walls of vessel, such that the dilutions would give final ratios of 4:1, 5:1, 6:1 and 7:1 (l FuGENE 6:g DNA). These were left for 5 min at room temperature. Each FuGENE 6 dilution was added drop wise to pCMVLuc at 400 g/ml in HEPES-buffered RPMI-1640 to give a final concentration of 20 g/ml DNA. Complexes were incubated for 15 min at room temperature before addition to cells. Superfect: pCMVLuc at 16.6 g/ml in HEPES-buffered RMPI-1640 was mixed with Superfect diluted appropriately in HEPES-buffered RPMI-1640 to give ratios of 1:1, 2:1, 5:1 and 10:1 (l Superfect:g DNA), and a final DNA concentration of 10 g/ml. Complexes were incubated for 10 min then diluted with transfection media (without FCS) to 3.3 g/ml before addition to cells.
Tfx reagents: 3.1 mg, 1.6 mg and 0.7 mg of Tfx-10, -20 and -50 respectively, were dissolved in nuclease-free water to 1 mm. Samples were vortexed, incubated at 65°C for 1 min, vortexed again and frozen overnight at −20°C for 30 min, thawed out and re-vortexed. Volumes of each Tfx reagent were added to 300 l pCMVLuc DNA at 10 g/ml in HEPES-buffered RPMI-1640 to give ratios of 3:1, 4.5:1 6:1 and 7.5:1 (l Tfx reagent:g DNA), equivalent to charge ratios of 2, 3, 4 and 5. HEPES-buffered RPMI-1640 was added to maintain final DNA concentration at 9.3 g/ml. Complexes were allowed to incubate for 10-15 min at room temperature before addition to cells.
Transfections
All ␤gal transfections were carried out in six-well plates. HepG2 and KLN 205 were seeded at 1 × 10 5 cells per well, 18-20 h before transfection. Immediately before transfection, cells were washed once with 1-2 ml of RPMI-1640 and 875 l of RA transfection medium (RPMI-1640 containing 0.1% human serum albumin), containing where appropriate 90 m chloroquine for HepG2 and 120 m chloroquine KLN 205, was added to each well followed by 125 l of DNA complexes at 20 g DNA/ml (prepared as described above). Medium in wells was mixed up and down with a pipette tip to ensure thorough dispersion of the complexes. All points in transfection assays were carried out in triplicate. Transfection medium was used as a negative control. Plates were then incubated at 37°C for 5 h (unless otherwise specified) and media replaced with 3 ml fresh growth medium and incubated for a further 18-24 h before ␤gal reporter assay.
For all cell types except human DC, GFP transfections were carried out in six-well plates, seeded 18-20 h before transfection at the densities indicated in the Figures. Immediately before transfection, cells were washed once with 1-2 ml of PBS and typically 875 l of RA transfection medium (or M199 containing 10% FCS for HUVEC) was added to each well followed by 125 l of DNA complexes at 20 g/ml (prepared as described above). To vary DNA dose the volume of DNA complexes was varied, maintaining the final volume on cells at 1 ml. Medium in wells was agitated as above to ensure thorough dispersion of the complexes. Plates were incubated at 37°C for 5 h (or 2 h for HUVEC) and media replaced with 3 ml fresh growth medium appropriate for the cell type and incubated for a further 18-24 h before FACScan analysis. For GFP transfection of human DC, cells were Gene Therapy washed with PBS, resuspended in RA transfection medium containing nonessential amino acids, 50 ng/ml transferrin (Sigma) and 50 m ␤-mercaptoethanol. DNA complexes were then added followed by chloroquine to 40 m and the cells plated 1 ml/well into 24-well plates at 3 × 10 5 cells per well, 2.5 mg DNA per well, followed by centrifugation at 1000 r.p.m. for 5 min to sediment cells and complexes. Plates were incubated at 37°C for 1.5 h and media replaced with 1 ml fresh human DC growth medium, then incubated for a further 18-24 h before FACScan analysis.
Luciferase transfections were carried out in 96-well plates. HepG2 cells and HUVEC were seeded at 5 × 10 4 and 1 × 10 4 cells per well, respectively, 18-20 h before transfection. Immediately before transfection, cells were washed once with 100 l of PBS and then placed in transfection media (HEPES-buffered RPMI-1640 for HepG2 and M199 for HUVEC, both containing antibiotics: penicillin and streptomycin, unless otherwise stated). Transfection complexes were added to the cells in triplicate wells, to give a final dose of 0.2 g per well DNA, and a final volume of 100 l. FCS was included in the transfection media such that after addition of complexes the final FCS concentration was 10%. After addition of complexes, plates were centrifuged for 5 min at 200 g to pellet the complexes on to the surface of cells. HepG2 cells were transfected for 4 h at 37°C under atmospheric CO 2 , and HUVEC for 1 h at 37°C under 5% CO 2 . After the transfection period, cells were washed with 100 l per well PBS, and incubated overnight at 37°C in cell growth media before luciferase reporter assay.
Reporter assays
Total ␤gal enzyme activity was measure using GalactoLight reagents (PE-Biosystems). Cells (in six-well plates) were washed once with PBS and lysed with 250 l per well lysis buffer. Cell debris was removed by centrifugation at 12 000 g and 10 l of the resulting supernatant added to 100 l Galacto-Light reaction buffer, incubated for 1 h, then assayed on Lumat LB9501 luminometer (Berthold, Pforzheim, Germany), with light emission measured over 10 s. Samples giving off-scale readings were diluted appropriately and re-read. The percentage of cells transfected with ␤gal was determined by X-gal staining. Cells (in six-well plates) were washed once with PBS, fixed with 0.05% glutaraldehyde for 10 min, washed again, then stained with X-gal solution (Life Technologies) and incubated overnight at 37°C. Positively-stained cells were counted and expressed as percentage of total cells in a field of view.
For analysis of GFP expression (in six-well plates), cells were removed with trypsin-EDTA, washed with PBS, and the percentage of expressing cells determined using a Becton Dickinson FACscan, with mock-transfected cells as autofluorescence controls. A marker region was set on a FL-1H histogram plot that contained none or very few of the mock-transfected cells, and this marker was then used to measure the number of GFP-expressing cells in the transfected populations. For human DC (in 24-well plates) the procedure was similar except that cells were dislodged by pipette and washed once with PBS before FACScan analysis.
Total luciferase enzyme activity was determined using Luc Screen reagents (PE-Biosystems). Two hundred l/well of Luc Screen reagent was added directly to the 100 l tissue culture media on cells in 96-well plates and the plates shaken gently for 10 min at room temperature. 250 l was removed and transferred to corresponding wells of black 96-well plates (Packard Bioscience, Pangbourne, UK) (to prevent well to well cross-talk) and luminescence read using a TopCount scintillation counter (Packard Bioscience) in SPC mode and a count time of 0.02 min. Results expressed as c.p.s. per well.
Cellular uptake of complexes
Uptake experiments were carried out with KLN 205 cells seeded 18-24 h previously at 1 × 10 5 cells per well in sixwell plates, using the method for transfections except that plasmid DNA was pre-labelled with YOYO-1 (Molecular Probes, Leiden, The Netherlands) 1 molecule per 100 base pairs, and then condensed with peptides. YOYO-1 labelled complexes were incubated with cells for 4 h at 4°C and 37°C in RPMI-1640 containing 120 m chloroquine, after which cells were removed with trypsin-EDTA, washed twice with PBS, and fluorescence determined by FACScan analysis.
